文献速递心外重症与机械循环支持

左心室辅助装置接受者长期生存相关因素

Factors Associated With Prolonged Survival in Left Ventricular Assist Device Recipients.
PubMed 文献 · Ann Thorac Surg · 2018-10-11

该回顾性研究基于INTERMACS数据库,纳入2012年5月至2013年3月首次连续流左心室辅助装置接受者,以6个月初始生存为条件分析3年后仍带装置生存的相关因素。1116例中725例(65%)生存超过3年;多因素分析显示糖尿病、胺碘酮使用及6个月内发生卒中、胃肠道出血、溶血或泵血栓与3年死亡风险增加相关。

要点

  • 糖尿病与胺碘酮使用与LVAD接受者长期生存不良相关
  • 6个月内卒中、消化道出血、溶血或泵血栓提示长期预后差
  • 早期诊断与处理上述并发症可能改善LVAD接受者生存

核心结论

  • 术前糖尿病和胺碘酮使用与LVAD接受者长期生存不良相关。
  • 6个月内发生卒中、胃肠道出血、溶血或泵血栓也与长期生存不良相关。

研究设计与样本

  • 回顾性分析INTERMACS数据库,纳入2012年5月至2013年3月首次连续流LVAD接受者。
  • 以初始存活6个月为条件,比较3年后仍带装置生存与否,排除移植、因恢复拔除装置或3年前失访者。
  • 采用多因素logistic回归评估围术期因素及6个月内不良事件与长期生存的关联。

主要发现

  • 1116例存活超过初始6个月的患者中,725例(65%)生存超过3年。
  • 单因素分析显示长期生存者显著更年轻、白人比例更低、目的地治疗更少,糖尿病、实体器官肿瘤或胺碘酮使用更少。
  • 多因素分析显示糖尿病、胺碘酮使用及6个月内卒中、胃肠道出血、溶血或泵血栓与3年死亡风险增加相关。

临床怎么用

  • 对LVAD候选者评估糖尿病和胺碘酮使用等术前因素以识别长期生存风险。
  • 植入后6个月内重点监测并早期处理卒中、胃肠道出血、溶血和泵血栓。

局限性

  • 回顾性研究设计。
  • 数据来源于INTERMACS注册登记,时限为2012年5月至2013年3月。
  • 排除了移植、因恢复拔除装置或3年前失访者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Limited data exist on factors predicting prolonged survival in left ventricular assist device (LVAD) recipients. We sought to identify patient characteristics and complications associated with prolonged survival. METHODS: We conducted retrospective review of the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) database, including primary continuous-flow LVAD recipients, between May 2012 and March 2013. Patients were identified as having survived with a device in place after 3 years or not, conditional on having initially survived 6 months. Patients who received a transplant, underwent explant due to recovery, or were lost to follow-up before 3 years were excluded. Multivariate logistic regression evaluated perioperative factors and adverse events within 6 months associated with long survival. RESULTS: Of 1,116 patients who survived past the initial 6 months, 725 (65%) survived beyond 3 years. On univariate analysis, long-term survivors were significantly younger, were less likely to be white, supported for destination therapy, have diabetes, solid-organ cancer, or take amiodarone. On multivariate analysis, factors associated with increased odds of death at 3 years included diabetes, amiodarone use, and developing stroke, gastrointestinal bleeding, hemolysis, or pump thrombosis within 6 months of implantation. CONCLUSIONS: Preoperative diabetes and amiodarone use were associated with poor long-term survival in LVAD recipients. Development of early complications of stroke, gastrointestinal bleeding, hemolysis, or pump thrombosis was also associated with poor long-term survival. Early diagnosis and treatment of these complications may improve survival in LVAD recipients.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Xia Y, Forest S, Friedmann P, et al. Factors Associated With Prolonged Survival in Left Ventricular Assist Device Recipients. Ann Thorac Surg. 2018. PMID: 30316851. doi:10.1016/j.athoracsur.2018.08.054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。